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Background: Exacerbations of chronic obstructive pulmonary disease (COPD) contribute significantly to disease
progression. However, the effect on tissue structure and turnover is not well described. There is an urgent clinical
need for biomarkers of disease activity associated with disease progression. Extracellular matrix (ECM) turnover
reflects activity in tissues and consequently assessment of ECM turnover may serve as biomarkers of disease activity.
We hypothesized that the turnover of lung ECM proteins were altered during exacerbations of COPD.
Methods: 69 patients with COPD hospitalised for an exacerbation were recruited at admission and returned for a 4
weeks follow-up. Competitive ELISAs measuring circulating protein fragments in serum or plasma assessed the
formation and degradation of collagen types III (Pro-C3 and C3M, respectively), IV (P4NP 7S and C4M, respectively),
and VI (Pro-C6 and C6M, respectively), and degradation of elastin (ELM7 and EL-NE) and versican (VCANM).
Results: Circulating levels of C3M, C4M, C6M, ELM7, and EL-NE were elevated during an exacerbation of COPD
as compared to follow-up (all P <0.0001), while VCANM levels were decreased (P <0.0001). Pro-C6 levels were
decreased and P4NP 7S levels were elevated during exacerbation (P <0.0001). Pro-C3 levels were unchanged.
At time of exacerbation, degradation/formation ratios were increased for collagen types III and VI and decreased for
collagen type IV.
Conclusions: Exacerbations of COPD resulted in elevated levels of circulating fragments of structural proteins, which
may serve as markers of disease activity. This suggests that patients with COPD have accelerated ECM turnover during
exacerbations which may be related to disease progression.
Keywords: COPD, Exacerbation, Extracellular matrix, Tissue turnover, Collagens, Elastin, Versican, Disease
activity, BiomarkersBackground
Chronic obstructive pulmonary disease (COPD) is a
heterogeneous, slow progressing disease characterized
by persistent airflow limitation resulting from chronic
inflammation, structural changes, and small airway
narrowing [1]. The main structural proteins of the
extracellular matrix (ECM) of the lung are collagens,
elastin, and proteoglycans. ECM turnover is part of
healthy tissue maintenance, where old proteins are* Correspondence: jsa@nordicbioscience.com
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excessive ECM turnover may drive the structural
changes in COPD and promote loss of lung function. A
key challenge in COPD is the identification of
biomarkers of disease progression [3]. ECM investigation
by assessment of lung structural proteins may provide
biomarkers of disease activity and prognosis. Novel
technologies assessing ECM protein turnover are
promising candidate tools [4, 5].
Exacerbations are periods of increased disease
activity that drive COPD progression by accelerating
loss of lung function [6], reducing quality of life [7],
and causing mortality [8]. Patients in all COPD stages
may experience exacerbations, although they become
more frequent with increasing disease severity [9]. Itcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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predictor of future exacerbations is an exacerbation
history [9, 10]. Although exacerbations are key events
in COPD pathogenesis, little is known regarding
structural changes in lung tissue during these events.
Matrix metalloproteinase 9 (MMP-9) levels are known
to be elevated while tissue inhibitor of metalloprotein-
ase 1 (TIMP-1) levels are decreased in sputum of
COPD patients at time of exacerbation compared to
stable COPD [11], suggesting a destructive environ-
ment. In the present work we tested the hypothesis
that ECM turnover, assessed systemically by bio-
markers of protein degradation and formation, would
be accelerated during an exacerbation of COPD where
disease activity is high.Methods
Study design
Patients presenting with a hospital admission deemed
by a medical consultant to be a COPD exacerbation
during 2011 and 2012 were recruited within 24 h of
admission. All patients provided written informed
consent, and the study was approved by the National
Research Ethics Service (10/H0403/85). Blood samples
were collected at time of exacerbation and at recovery: a
4 week follow-up visit performed a median of 30 (IQR
28–34) days after admission. At follow-up visit, the
patients underwent standard post-bronchodilator spir-
ometry, and performed a six minute walking distance
(6MWD). Patient-reported measures included assess-
ments of dyspnoea, using the Medical Research
Council (MRC) dyspnoea scale, at follow-up visit, and
smoking history. The inclusion criterion was a clinical
diagnosis of acute COPD exacerbation at hospital ad-
mission made by a consultant physician. A physician
diagnosis or radiological evidence of pneumonia was an
exclusion criterion. The study comprised 69 patients withTable 1 Overview of the assays used in this study to assess extracel




C3M Collagen type III degraded by MMPs 5.52–177 3.4
C4M Collagen type IV degraded by MMPs 22.8–748 4.2
C6M Collagen type VI degraded by MMPs 4.88–420 8.0
ELM7 Elastin degraded by MMP-7 1.16–36.6 8.1
EL-NE Elastin degraded by neutrophil elastase 1.76–167 8.6
VCANM Versican degraded by MMPs 0.78–7.13 3.0
Pro-C3 Collagen type III propeptide (N-terminal) 5.32–96.4 6.5
P4NP 7S Collagen type IV 7S domain 32.9–3460 9.4
Pro-C6 Collagen type VI C5 domain 0.30–117 4.8
The reference level was provided by the manufacturer (Nordic Bioscience) and refe
serum (C3M, C4M, Pro-C3, P4NP 7S, ELM7, EL-NE) or plasma (C6M, Pro-C6, VCANM).paired samples and with airflow obstruction (ratio of
forced expiratory volume in one second (FEV1) to forced
vital capacity (FVC) of <0.7) confirmed at follow-up visits.Biomarkers
Serum and plasma samples were stored at –80 °C
until analysed. C3M, C4M, Pro-C3, P4NP 7S, ELM7,
and EL-NE, were measured in serum, while C6M,
Pro-C6, and VCANM were measured in plasma. All
assays employed a monoclonal antibody directed
against either a protein fragment produced by prote-
ase cleavage during degradation or formation, or an
internal protein sequence. An overview of the assays
used in this study and their technical specifications is
given in Table 1. All samples were measured within
the detection range of each assay and any sample
with values below the lower limit of detection
(LLOD) was assigned the value of LLOD.Statistical analysis
The main outcome predictor was change in circulating
levels of C3M, C4M, C6M, Pro-C3, P4NP 7S, Pro-C6,
ELM7, EL-NE, and VCANM. Based on previous data for
these assays, for 90 % power to detect a 20 % difference
in biomarker levels between exacerbation and follow-up
with a two-sided α of 0.05, a minimum of 27 to 55 pa-
tients were required. Biomarker levels were normalised
by log-transformation. Exacerbation and follow-up
values were compared by paired t-test. Univariate and
multivariate linear regressions were performed using the
log-transformed biomarker data to identify associations
with clinical parameters. The multivariate analysis
included age, gender, body mass index (BMI), smoking
pack years, and smoking status as additional explanatory
variables. P <0.05 was considered significant. Analyses
were performed using MedCalc Statistical Software v.12
(MedCalc Software, Ostend, Belgium).lular matrix turnover
a-and inter-assay
iation (%)
Reference level (ng/ml), mean (SD) References
and 9.8 15.3 (3.8) [28]
and 18.5 55.4 (17.8) [29]
and 11.0 8.85 (5.1) [30]
and 9.1 2.23 (0.74) Preliminary data
and 12.9 4.09 (2.24) [31]
and 7.6 1.20 (0.23) [32]
and 12.4 12.3 (4.4) [33]
and 14.2 263 (91.3) [34]
and 15.2 4.37 (0.69) Preliminary data
rs to the biomarker level of a healthy population in the relevant matrix, i.e.
SD, standard deviation; MMP, matrix metalloproteinase
Table 3 Biomarker levels at exacerbation and 4 weeks follow-up
Exacerbation (ng/ml) Follow-up (ng/ml) P value
C3M 29.24 [26.32–32.49] 22.64 [20.78–24.67] <0.0001
C4M 95.96 [85.83–107.28] 73.30 [66.59–80.69] <0.0001
C6M 19.78 [16.82–23.27] 13.27 [11.56–15.23] <0.0001
ELM7 4.26 [3.90–4.64] 3.61 [3.37–3.87] <0.0001
EL-NE 7.79 [6.30–9.63] 5.23 [4.41–6.21] <0.0001
VCANM 1.69 [1.58–1.80] 1.87 [1.78–1.97] 0.0001
Pro-C3 12.10 [10.60–13.81] 12.79 [11.35–14.42] 0.2549
P4NP 7S 510.99 [440.91–592.21] 359.20 [312.28–413.17] <0.0001
Pro-C6 5.36 [4.81–5.99] 6.38 [5.71–7.14] <0.0001
Results are presented as geometric mean [95 % confidence interval] and
corresponding P values comparing circulating biomarker levels at time of
exacerbation and follow-up
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Basic demographics
Patient demographics and clinical characteristics are
summarised in Table 2. Patients were mostly men (71 %)
and ex-smokers (55 %). They were hospitalised for a
median [IQR] of 3 [2–6] days, and follow-up visit was
performed at 30 [28–34] days after admission.
Protein turnover during COPD exacerbation
Circulating levels of protein fragments released at
time of exacerbation and at a clinically stable disease
period at 4 weeks follow-up are presented in Table 3.
Degradation fragments of collagen type III (C3M),
collagen type IV (C4M), collagen type VI (C6M), and
elastin (ELM7 and EL-NE) were significantly elevated
at exacerbation compared to follow-up (all P <0.0001;
Fig. 1a-e). In contrast, a fragment of versican degrad-
ation (VCANM) showed a significantly decreased
mean level at time of exacerbation (P <0.0001; Fig. 1f ).
Levels of fragments related to protein formation
were not significantly changed for collagen type III
(Pro-C3), but were increased for collagen type IV
(P4NP 7S; P <0.0001) and decreased for collagen
type VI (Pro-C6; P <0.0001) at exacerbation compared
to follow-up (Fig. 1g-i). To investigate the effect of
smoking on circulating levels of protein fragments,
analysis was performed on current and ex smokers,
individually, with similar results (data not shown).
Collagen degradation/formation balance
The balance between degradation and formation of col-
lagens was investigated by calculating the ratio betweenTable 2 Basic characteristics of the COPD population at follow-up
visit 4 weeks after exacerbation onset
Variable Patients (n = 69)
Age (years), median (IQR) 67 (61–75)
Female sex, n (%) 20 (29)
BMI (kg/m2) 25.7 (6.3)
Current smokers, n (%) 31 (45)
Smoking pack years (years) 52 (26)
Length of hospitalisation (days), median (IQR) 3 (2–6)
FEV1 (liters) 1.19 (0.50)
FEV1 (% of predicted) 45.8 (16.1)
FVC (liters) 2.55 (0.81)
FVC (% of predicted) 77.5 (19.0)
FEV1/FVC ratio 0.46 (0.11)
6MWD (meters) 166 (119)
MRC dyspnoea score, median (IQR) 4 (3–4)
Variables are listed as mean (standard deviation) unless otherwise stated. IQR,
interquartile range; BMI, body mass index; FEV1, forced expiratory volume in
one second; FVC, forced vital capacity; 6MWD, 6 min walking distance; MRC,
Medical Research Councilfragments of degradation and formation for collagen
types III, IV, and VI (Fig. 2). The mean degradation/for-
mation ratio [95 % CI] was significantly elevated at time
of exacerbation for collagen type III (2.33 [2.03–2.66] vs.
1.72 [1.51–1.96], P <0.0001) and collagen type VI (3.61
[2.86–4.56] vs. 2.00 [1.64–2.44], P <0.0001). In contrast,
the collagen type IV degradation/formation ratio was
0.18 [0.17–0.20] at exacerbation and increased to 0.20
[0.19–0.22] at follow-up (P = 0.0008).
Associations with clinical parameters
At follow-up, C3M was positively associated with
BMI (r = 0.245, P = 0.049), Pro-C6 was positively as-
sociated with age (r = 0.317, P = 0.022), and EL-NE
was positively associated with white blood cell count
(r = 0.279, P = 0.022). No associations were seen with
smoking pack years, MRC score, length of hospital-
isation, or sputum production. Pro-C3 levels were
positively associated with FEV1 % of predicted value
(%pred) and FVC %pred, and these remained signifi-
cant after correcting for age, gender, BMI, smoking
pack years, and smoking status (Table 4). 6MWD
was negatively associated with C3M, C4M, C6M, and
P4NP 7S (Table 4). Following correction for age,
gender, BMI, smoking pack years, and smoking sta-
tus, associations with C3M and C6M remained sig-
nificant (Table 4).
Discussion
To our knowledge, this is the first study describing
that COPD exacerbations are associated with acceler-
ated tissue turnover by measuring circulating levels of
ECM protein fragments during and after an exacerba-
tion. These results indicate that the processing of
structural proteins in the lungs is altered during
severe exacerbations as compared to a clinically stable
disease period at 4 weeks follow-up. The main find-
ings were; 1) significantly elevated levels of circulating
Fig. 1 Biomarker levels at time of exacerbation and at 4 weeks follow-up. a-f Levels of degradation fragments of collagens type III (serum C3M),
IV (serum C4M), and VI (plasma C6M), elastin (serum ELM7 and EL-NE) and versican (plasma VCANM). g-i Levels of fragments released in relation
to formation of collagen types III (serum Pro-C3), IV (serum P4NP 7S), and VI (plasma Pro-C6). Results are shown as geometric mean with 95 %
confidence intervals. Biomarker levels at exacerbation and follow-up were compared using paired t-test. Significance levels: ***P <0.001,
****P <0.0001
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and VI (C6M), and elastin (ELM7 and EL-NE) deg-
radation were found at time of exacerbation as com-
pared to follow-up; 2) at exacerbation, levels of
circulating biomarkers released in relation to protein
formation was significantly elevated for type IV colla-
gen, whereas it was significantly decreased for type VIcollagen, and unchanged for type III collagen; 3) the
tissue turnover balance, assessed systemically by the
collagen degradation/formation ratio, was increased
for type III and VI collagen and decreased for type
IV collagen; 4) circulating levels of Pro-C3 were asso-
ciated with disease severity, assessed by FEV1 %pred
and FVC %pred, while C3M, C4M, C6M, and P4NP
Fig. 2 Ratios between collagen degradation and formation at time of exacerbation and at 4 weeks follow-up. Degradation/formation ratio
of a collagen type III calculated by serum C3M/Pro-C3, b collagen type IV calculated by serum C4M/P4NP 7S, and c collagen type VI
calculated by plasma C6M/Pro-C6. Results are shown as geometric mean with 95 % confidence intervals. Ratios at exacerbation and
follow-up were compared using paired t-test. Significance levels: ***P <0.001, ****P <0.0001
Sand et al. Respiratory Research  (2015) 16:69 Page 5 of 87S were associated with exercise capacity, assessed by
6MWD.
Structural ECM proteins are crucial for maintaining
tissue function. Collagens provide flexibility and form a
scaffold for cells, elastin provides tissue elasticity, and pro-
teoglycans such as versican maintain ECM integrity by
interacting with hyaluronan. Others have investigated the
collagen turnover by different technologies. O’Reilly et al.
reported elevated sputum proline-glycine-proline (PGP), a
neutrophil chemoattractant derived from collagen degra-
dation, around the time of exacerbation in a small cohort
of COPD patients [12]. Further, azithromycin treatmentTable 4 Associations between biomarker levels and clinical
parameters
FEV1 %pred FVC %pred 6MWD
C3M −0.118 −0.201 −0.350** (−0.311*)
C4M −0.149 −0.161 −0.289* (−0.252)
C6M −0.096 −0.226 −0.403** (−0.354**)
ELM7 −0.090 −0.149 −0.178
EL-NE −0.039 −0.106 −0.186
VCANM −0.0004 −0.080 −0.067
Pro-C3 0.345* (0.320*) 0.313* (0.305*) 0.055
P4NP 7S −0.086 −0.193 −0.269* (−0.230)
Pro-C6 0.023 −0.046 −0.153
Results are presented as univariate correlation coefficients (r) for each marker.
In brackets are given multivariate correlation coefficients for markers showing
significant r. The multivariate linear regression analysis included age, gender,
BMI, smoking pack years, and smoking status as additional explanatory variables.
Significance levels: *P <0.05, **P <0.01. FEV1, forced expiratory volume in one
second; %pred, percentage of predicted value; FVC, forced vital capacity; 6MWD,
6 min walking distancetargeting exacerbations reduced sputum PGP. Their results
indicate that COPD exacerbation causes collagen destruc-
tion, resulting in PGP release. As the PGP motif exists in
several ECM proteins, especially collagens [13], and its spu-
tum levels reflect overall lung ECM degradation; we investi-
gated ECM turnover further by analysing different proteins.
Further, our study utilised samples from the same patients
4 weeks apart, providing insight into short-term changes in
protein turnover. We previously reported elevated bio-
marker levels, including serum C3M and C6M, in a small
cohort of mild COPD patients compared to healthy con-
trols [5]. Our previous study utilised early research and de-
velopment versions of some of the assays presented here,
resulting in somewhat different levels, but nevertheless in-
dicating that measuring protein fragments in the circulation
of patients with COPD may be of interest.
Collagens are the most abundant components of the
lung interstitium, and fibrillar collagens such as types I and
III maintain the lung architecture. Collagen type IV is the
main constituent of the basement membrane, a sheet-like
ECM structure underlying epithelial and endothelial cells.
Collagen type VI molecules form anchoring fibrils that can
interact with collagen types I and IV and fibronectin
thereby adhering to the interstitial matrix and basement
membrane, upholding tissue structure [14]. Our results in-
dicate that both the interstitial matrix and the basement
membrane were turned over faster during an exacerbation
and point to a destructive environment affecting several
structural proteins. Both formation and degradation of col-
lagen types III, IV, and VI were changed. Significantly de-
creased plasma Pro-C6 levels during a COPD exacerbation
suggest that collagen type VI formation was lower than
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type VI degradation/formation ratio was significantly ele-
vated during exacerbation when compared to follow-up,
indicating a balance shift towards collagen type VI degrad-
ation during exacerbation. As collagen type VI is involved
in reconstructing damaged tissue by stimulating fibroblast
proliferation and preventing apoptosis [15–17], its en-
hanced degradation during exacerbation may contribute
to COPD progression. It should be noted that the process
of proteins and peptides entering the circulation is not
fully understood. Different peptides may diffuse from the
lung tissue to the circulation in different manners. Thus,
the degradation/formation ratios cannot be interpreted
directly but may serve as an indication of the shift in the
balance between degradation and formation at time of ex-
acerbation and follow-up. The ratio as such does not pro-
vide any information on the degree of protein formation
and degradation. Collagen type III formation was not
affected by exacerbation as shown by unaltered levels of
serum Pro-C3. However, degradation (serum C3M) and
degradation/formation ratio were significantly elevated
during exacerbation, suggesting an overall collagen type
III destruction during these episodes. As collagen type III
is an abundant lung ECM protein, its destruction may
greatly alter tissue function. Interestingly, serum Pro-C3
was the only biomarker directly associated with FEV1
%pred, indicating a relation to disease severity rather than
activity. Levels of serum C4M and P4NP 7S were signifi-
cantly increased during exacerbation compared to follow-
up. This indicated that both formation and degradation of
collagen type IV were elevated during exacerbation, result-
ing in an accelerated turnover rate. The balanced outcome
of this turnover showed a decreased degradation during
exacerbation compared to follow-up, as shown by the
C4M/P4NP 7S ratio. C3M, C4M, C6M, and P4NP 7S
were negatively associated with 6MWD, indicating an in-
teresting relationship between exercise capacity and colla-
gen turnover that should be investigated further.
Elastin degradation by MMP-7 and neutrophil elastase
was increased during exacerbation, as shown by elevated
levels of serum ELM7 and EL-NE, respectively. Elastin
provides lungs with elasticity, allowing movement during
breathing and preservation of the lung structure and func-
tion. Neutrophil elastase is released by neutrophils which
are abundant during tissue inflammation [18], and degrad-
ation of elastin by neutrophil elastase (EL-NE) may reflect
the local inflammatory response. Neutrophil elastase ac-
tivity towards fibrinogen and the proportion of blood
neutrophils are elevated during a COPD exacerbation
compared to stable disease [19, 20], demonstrating a role
of neutrophil elastase in exacerbations. Our data support
this finding by showing increased activity of neutrophil
elastase towards elastin at time of exacerbation. Although
our results for ELM7 and EL-NE were similar, it isimportant to recognize the difference in the assays and
the value of knowing exactly what epitope the antibody
targets [21].
Interestingly, plasma VCANM was decreased during
exacerbation, implying that versican processing is differ-
ent to other ECM proteins. Versican degradation is
linked to vascular diseases, suggesting that proteolytic
modifications have pathophysiological implications for
the vascular system [22]. However, versican also seems
to play an important role in the lungs and versican
content in the lungs is increased in COPD patients
compared to controls [23, 24]. The increased versican
content is believed to inhibit the function of elastin
binding protein (EBP), thus impairing formation of
elastic fibers [25]. An increased versican content in the
lungs was associated with decreased elastin and EBP
content and a decrease in FEV1 [23] supporting a differ-
ent role for versican compared with elastin and collagens
in COPD.
Exacerbations of COPD are periods of increased
disease activity, when the biological processes that drive
disease progression may be accelerated [26]. While FEV1
is a measure of disease severity it is not a good measure
of disease activity, and a low FEV1 does not necessarily
reflect a fast disease progression [3]. The rate of decline
in FEV1 represents a better measure of disease activity
or disease progression [3, 27]. However, measuring the
rate of decline in FEV1 requires very large and long-term
studies, making it impractical for assessment of new
disease-modifying treatments [3]. The recent ATS/ERS
statement on research questions in COPD proposes
measures of lung tissue destruction as potential bio-
markers of disease activity and recommends further
studies on disease activity biomarkers [26]. The results
presented here indicate that biomarkers of lung ECM
turnover may be markers of disease activity as circu-
lating levels are elevated during exacerbation. These
markers assess protease-generated protein fragments, also
known as protein fingerprints [21], derived from tissue.
The assays used are very sensitive, allowing measurements
of low abundance protein fragments in circulation. This
provides an indirect measure of tissue turnover in the
lung, which may reflect disease activity. This assessment
may better reflect dynamic remodelling of lung tissue
compared to spirometry measures, which in the stable
state reflect the cumulative disease process and reflect
both the baseline level and the additional bronchocon-
striction during the acute exacerbation. Future studies on
the ECM turnover in patients classified as slow or fast
progressors may reveal if patients with higher disease
activity have elevated biomarker levels also in the stable
state. Reliable markers of disease activity are an urgent
need in the field of COPD as they have the potential to
improve and shorten the assessment of new treatments [3].
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systemically may originate from multiple organs, thus
introducing a background level from other tissues.
However, the turnover in healthy tissue is balanced and
occurs at a slow pace with release of low levels of pro-
tein fragments. In this study we compared circulating
levels in a patient group at two time points, minimising
the risk that observed differences are not the cause of
the exacerbation. Future studies should assess the ECM
turnover in sputum for comparison, eliminating the
extra-pulmonary contribution. Another limitation was
that treatment for exacerbation may influence protein
turnover. However, irrespective of treatment this study
showed accelerated ECM turnover during exacerbation.
This study represents daily clinical practice for COPD
patients admitted to hospital for an exacerbation, thus it
includes patients on different treatment regimens and
with exacerbation from different causes. Further, co-
morbidities may influence biomarker levels and the lack
of information on these is a limitation, however the
paired design of this study may eliminate some of the
effect. Although patients did not have evidence of myo-
cardial infarction or other significant events during
hospitalisation, we cannot exclude that subclinical events
may have occurred affecting the levels of the measured
biomarkers. Future studies should explore the effect of
treatment and co-morbidities on ECM turnover as well
as exacerbation aetiology.Conclusions
We have shown that during an acute exacerbation of
COPD there is an accelerated turnover of ECM proteins
relevant to lung. The enhanced protein turnover is likely
to be important in COPD progression. Assessment of
these biomarkers may provide useful endpoints in proof-
of-concept studies aiming at reducing lung tissue turn-
over during exacerbations.Abbreviations
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